Iconovo’s expertise in developing inhalers and inhalation platforms for treating respiratory diseases has been key to generating several important collaborations. The latest comes in the form of a research partnership with Biofilms – Research Center for Biointerfaces at Malmö University and Swedish biotech Nanologica to develop an inhalation platform based on porous drug carriers. The collaboration could result in a breakthrough in inhalation therapy.
The lung infection caused by Mycobacterium tuberculosis, the bacteria that cause Tuberculosis (TB), is estimated to lead to 5,000 deaths each day, globally. In treating the disease, one of the major therapeutic challenges is to deliver a sufficiently high dose of the medication to the infected area of the lungs. In most cases, inhalation therapies are recommended, but reaching high enough doses is still an issue.